Abstract
The article discusses particular circumstances of acute coronary syndrome (ACS) in patients with type 2 diabetes (T2D). In addition, the available literature data and clinical guidelines reflecting the role of hypoglycemic therapy as a cardioprotection factor in ACS are analyzed. The article considers possible protective molecular mechanisms of various groups of drugs in ischemic cardiomyocytes.
Funding Information
  • the Russian state-funded project for Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences (121031300045-2, 122031700094-5)
  • Research Institute of Internal and Preventive Medicine—Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (121031300045-2, 122031700094-5)

This publication has 61 references indexed in Scilit: